GUIDELINES DEVELOPED BY PSANZ
PSANZ Policy on Marketing of Infant Formula
At its meeting in April 2017, the PSANZ Board discussed its position with regard to the acceptance of sponsorship from companies marketing infant formula products.
The Board acknowledged that there was a duality with two distinct interests coexisting, namely a pecuniary interest as well as a responsibility for the Society to advocate breast feeding as preferred whenever possible. These interests were recognised as operating in a contradictory manner and therefore a conflict of interest. The conflict of interest was such that ambiguity about goals and values could adversely affect the community and the Society. The Board resolved to manage this conflict of interest by making a clear declaration to maintain openness and transparency, and to develop appropriate processes to deal with the specific issues around the conflict of interest.
The Society has conversed widely, including with the President of The UK College of Paediatrics and Child Health. PSANZ has developed guidelines and principles:
PSANZ Position Statement on pre-pregnancy obesity
We are pleased to announce the release of the PSANZ Position Statement on pre-pregnancy obesity. This position statement has been developed by a multidisciplinary working group of PSANZ members and has been endorsed by the Royal Australasian College Physicians. Click here to download the Position Statement.
Clinical practice guideline for the management of women who report decreased fetal movements
Using an evidence-based approach, this guideline aims to improve the management and outcome of care for women with DFM. The guideline covers 2 key areas, namely information provided to pregnant women regarding DFM, and management protocols for clinicians caring for women presenting with DFM.
You can download the current guideline from here.
PSANZ Clinical Practice Guideline for Perinatal Mortality
The main purpose of the guideline is to enable a high quality systematic approach to the provision of care around the time of a perinatal death including investigation and audit and bereavement care for parents across Australia and New Zealand (ANZ).
The guideline is currently under review and an updated version will be available in 2016.
OTHER GUIDELINES ENDORSED BY PSANZ
National Antenatal Guidelines – Module 1
Please click here for further information relating to the National Antenatal Guidelines.
Antenatal Corticosteroid Guidelines
Evidence-based recommendations to guide decision-making in clinical practice in New Zealand and Australia.
To view the final version of "Antenatal Corticosteroids given to women prior to birth to improve fetal, infant, child and adult health: New Zealand and Australian clinical practice guidelines 2015", please click here.
WHO Preterm Birth Guidelines
WHO envisions a world where every woman and newborn receives quality care throughout pregnancy, childbirth and the postnatal period. One of the critical strategic areas identified by WHO to realise this vision is the development and dissemination of evidence-based guidelines to improve quality of care around the time of childbirth, including care to improve survival of babies born too soon or too small.
Today, WHO launches new guidance to improve pregnancy outcomes of women at imminent risk of preterm birth, and to improve neonatal outcomes of preterm infants soon after birth. The WHO recommendations on interventions to improve preterm birth outcomes are now available and can be accessed here.
This guideline contains 27 individual recommendations related to the use antenatal corticosteroids, tocolytics, antibiotics, magnesium sulfate (for fetal, infant and child neuroprotection), and mode of delivery for pregnant women at imminent risk of preterm birth; and key newborn interventions related to the use of Kangaroo mother care, plastic bags / wraps, continuous positive airway pressure, surfactant, and safe oxygen therapy for the preterm infant after birth.
The guideline publication is accompanied by a commentary in Lancet Global Health, available here. This commentary highlights key messages and describes the rationale for making the recommendations in some controversial topics. An evidence brief that summarizes the recommendations, their justifications and important policy and programme actions for effective implementation is also available here.
There is more information on the guideline in the WHO feature stories. We encourage you to disseminate the guideline and the related publications through your networks. WHO welcomes comments and suggestions on the published documents and these should be directed to firstname.lastname@example.org, email@example.com or firstname.lastname@example.org.
You can learn more and contribute to further discussion by following @HRPresearch on twitter.